State transfer in dissipative and dephasing environments

By diagonalization of a generalized superoperator for solving the master equation, we investigated effects of dissipative and dephasing environments on quantum state transfer, as well as entanglement distribution and creation in spin networks. Our results revealed that under the condition of the same decoherence rate $\gamma$, the detrimental effects of the dissipative environment are more severe than that of the dephasing environment. Beside this, the critical time $t_c$ at which the transfer fidelity and the concurrence attain their maxima arrives at the asymptotic value $t_0=\pi/2\lambda$ quickly as the spin chain length $N$ increases. The transfer fidelity of an excitation at time $t_0$ is independent of $N$ when the system subjects to dissipative environment, while it decreases as $N$ increases when the system subjects to dephasing environment. The average fidelity displays three different patterns corresponding to $N=4r+1$, $N=4r-1$ and $N=2r$. For each pattern, the average fidelity at time $t_0$ is independent of $r$ when the system subjects to dissipative environment, and decreases as $r$ increases when the system subjects to dephasing environment. The maximum concurrence also decreases as $N$ increases, and when $N\rightarrow\infty$, it arrives at an asymptotic value determined by the decoherence rate $\gamma$ and the structure of the spin network.Comment: 12 pages, 6 figure

State transfer in intrinsic decoherence spin channels

By analytically solving the master equation, we investigate quantum state transfer, creation and distribution of entanglement in the model of Milburn's intrinsic decoherence. Our results reveal that the ideal spin channels will be destroyed by the intrinsic decoherence environment, and the detrimental effects become severe as the decoherence rate $\gamma$ and the spin chain length $N$ increase. For infinite evolution time, both the state transfer fidelity and the concurrence of the created and distributed entanglement approach steady state values, which are independent of the decoherence rate $\gamma$ and decrease as the spin chain length $N$ increases. Finally, we present two modified spin chains which may serve as near perfect spin channels for long distance state transfer even in the presence of intrinsic decoherence environments $\mathcal {F}{[\rho(t)]}$.Comment: 11 pages, 11 figure

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma driving alterations and suboptimal disease classification. We defined the complete set of genes associated with 1,122 diffuse grade II-III-IV gliomas from The Cancer Genome Atlas and used molecular profiles to improve disease classification, identify molecular correlations, and provide insights into the progression from low- to high-grade disease. Whole-genome sequencing data analysis determined that ATRX but not TERT promoter mutations are associated with increased telomere length. Recent advances in glioma classification based on IDH mutation and 1p/19q co-deletion status were recapitulated through analysis of DNA methylation profiles, which identified clinically relevant molecular subsets. A subtype of IDH mutant glioma was associated with DNA demethylation and poor outcome; a group of IDH-wild-type diffuse glioma showed molecular similarity to pilocytic astrocytoma and relatively favorable survival. Understanding of cohesive disease groups may aid improved clinical outcomes

DISSEMINATED BACILLUS-CALMETTE-GU蒖IN INFECTIONS AND PRIMARY IMMUNODEFICIENCY DISORDERS IN SINGAPORE: A SINGLE CENTER 15-YEAR RETROSPECTIVE REVIEW

10.1016/j.ijid.2020.05.117International Journal of Infectious Diseases97117-12

A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies

To determine the therapeutic efficacy (13-week and 26-week CNS progression-free survival [PFS], response rate, and overall survival) and safety of intraventricular (IVent) topotecan in patients with neoplastic meningitis (NM), we conducted a phase II, open-label, nonrandomized, single-arm trial of IVent topotecan in patients with NM using 400 μg of topotecan IVent twice weekly for 6 weeks, followed by evaluation with imaging, cerebrospinal fluid (CSF), and physical examinations. In the absence of disease progression, patients were then treated with IVent topotecan weekly for 6 weeks, twice monthly for 4 months, and monthly thereafter. Sixty-two patients (23 males and 39 females) were enrolled from April 2001 through March 2006. Median age and KPS at enrollment were 56 (range 5–83) and 80 (range 60–100), respectively. Primary cancers included breast (19), lung (13), CNS (14), and others (16). Forty patients (65%) completed the 6-week induction period, among whom 13 (21%) had CSF clearance of malignant cells. Kaplan-Meier estimates of PFS at 13 and 26 weeks were 30% (95% confidence interval [CI], 20%–45%) and 19% (95% CI, 11%–34%). Overall median survival (50 deaths) was 15 weeks (95% CI, 13–24 weeks). The most common side effect was chemical meningitis in 32% of patients (5% grade 3); 32% experienced no drug side effects. IVent topotecan is well tolerated, but provides no added benefit over other IVent therapies. Because of its modest side effect profile, combining IVent topotecan with other IVent or systemic interventions should be considered